Relevant bibliographies by topics / HIV pathogenicity; Gene therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'HIV pathogenicity; Gene therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV pathogenicity; Gene therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HIV pathogenicity; Gene therapy"

1

Munis, Altar M. "Gene Therapy Applications of Non-Human Lentiviral Vectors." Viruses 12, no. 10 (September 29, 2020): 1106. http://dx.doi.org/10.3390/v12101106.

Full text
Abstract:
Recent commercialization of lentiviral vector (LV)-based cell therapies and successful reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases and benefit patients. LVs hold notable and inherent advantages over other gene transfer agents based on their ability to transduce non-dividing cells, permanently transform target cell genome, and allow stable, long-term transgene expression. LV systems based on non-human lentiviruses are attractive alternatives to conventional HIV-1-based LVs due to their lack of pathogenicity in humans. This article reviews non-human lentiviruses and highlights their unique characteristics regarding virology and molecular biology. The LV systems developed based on these lentiviruses, as well as their successes and shortcomings, are also discussed. As the field of gene therapy is advancing rapidly, the use of LVs uncovers further challenges and possibilities. Advances in virology and an improved understanding of lentiviral biology will aid in the creation of recombinant viral vector variants suitable for translational applications from a variety of lentiviruses.
APA, Harvard, Vancouver, ISO, and other styles
2

White, Sarah M., Matthew Renda, Na-Yon Nam, Ekaterina Klimatcheva, Yonghong Zhu, Jennifer Fisk, Mark Halterman, et al. "Lentivirus Vectors Using Human and Simian Immunodeficiency Virus Elements." Journal of Virology 73, no. 4 (April 1, 1999): 2832–40. http://dx.doi.org/10.1128/jvi.73.4.2832-2840.1999.

Full text
Abstract:
ABSTRACT Lentivirus vectors based on human immunodeficiency virus (HIV) type 1 (HIV-1) constitute a recent development in the field of gene therapy. A key property of HIV-1-derived vectors is their ability to infect nondividing cells. Although high-titer HIV-1-derived vectors have been produced, concerns regarding safety still exist. Safety concerns arise mainly from the possibility of recombination between transfer and packaging vectors, which may give rise to replication-competent viruses with pathogenic potential. We describe a novel lentivirus vector which is based on HIV, simian immunodeficiency virus (SIV), and vesicular stomatitis virus (VSV) and which we refer to as HIV/SIVpack/G. In this system, an HIV-1-derived genome is encapsidated by SIVmac core particles. These core particles are pseudotyped with VSV glycoprotein G. Because the nucleotide homology between HIV-1 and SIVmac is low, the likelihood of recombination between vector elements should be reduced. In addition, the packaging construct (SIVpack) for this lentivirus system was derived from SIVmac1A11, a nonvirulent SIV strain. Thus, the potential for pathogenicity with this vector system is minimal. The transduction ability of HIV/SIVpack/G was demonstrated with immortalized human lymphocytes, human primary macrophages, human bone marrow-derived CD34+ cells, and primary mouse neurons. To our knowledge, these experiments constitute the first demonstration that the HIV-1-derived genome can be packaged by an SIVmac capsid. We demonstrate that the lentivirus vector described here recapitulates the biological properties of HIV-1-derived vectors, although with increased potential for safety in humans.
APA, Harvard, Vancouver, ISO, and other styles
3

Morice, Yoann, Dominique Roulot, Véronique Grando, Jérome Stirnemann, Elyanne Gault, Vincent Jeantils, Michelle Bentata, et al. "Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns." Journal of General Virology 82, no. 5 (May 1, 2001): 1001–12. http://dx.doi.org/10.1099/0022-1317-82-5-1001.

Full text
Abstract:
Hepatitis C virus (HCV) has been classified into six clades as a result of high genetic variability. In the Seine-Saint-Denis district of north-east Paris, the prevalence of HCV-4, which usually infects populations from Africa or the Middle East, is twice as high as that recorded for the whole of continental France (10·2 versus 4·5%). Although the pathogenicity of HCV-4 remains unknown, resistance of HCV-4 to therapy appears to be similar to that observed for HCV-1. In order to characterize the epidemiology of HCV-4 in Paris, sequences of the non-structural 5B gene (332 bp) were obtained from 38 HCV-4-infected patients. Extensive phylogenetic analyses indicated seven different HCV-4 subtypes. Moreover, phylogenetic tree topologies clearly distinguished two epidemiological profiles. The first profile (52·6% of patients) reflects the intra-suburban emergence of two distinct HCV-4 subclades occurring mainly among intravenous drug users (65% of patients). The second profile shows six subclades [HCV-4a, -4f, -4h, -4k, -4a(B) and a new sequence] and accounts for patients from Africa (Egypt and sub-Saharan countries) who have unknown risk factors (77·8% of patients) and in whom no recent diffusion of HCV-4 is evident. This study indicates the high diversity of HCV-4 and the extension of HCV-4a and -4d subclades among drug users in France.
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Gene therapy for HIV?" Inpharma Weekly &NA;, no. 1128 (March 1998): 11. http://dx.doi.org/10.2165/00128413-199811280-00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Voelker, R. "Gene therapy for HIV." JAMA: The Journal of the American Medical Association 275, no. 20 (May 22, 1996): 1533. http://dx.doi.org/10.1001/jama.275.20.1533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Voelker, Rebecca. "Gene Therapy for HIV." JAMA: The Journal of the American Medical Association 275, no. 20 (May 22, 1996): 1533. http://dx.doi.org/10.1001/jama.1996.03530440011009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Minton, Kirsty. "Gene therapy for HIV." Nature Reviews Immunology 4, no. 6 (June 2004): 400. http://dx.doi.org/10.1038/nri1386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bird, Lucy. "Gene therapy for HIV?" Nature Reviews Immunology 14, no. 4 (March 25, 2014): 215. http://dx.doi.org/10.1038/nri3655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lever, A. M. L. "Gene therapy for HIV." Sexually Transmitted Infections 77, no. 2 (April 1, 2001): 93–96. http://dx.doi.org/10.1136/sti.77.2.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Crenshaw, Brennetta J., Leandra B. Jones, Courtnee’ R. Bell, Sanjay Kumar, and Qiana L. Matthews. "Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy." Biomedicines 7, no. 3 (August 19, 2019): 61. http://dx.doi.org/10.3390/biomedicines7030061.

Full text
Abstract:
Human adenoviruses are large (150 MDa) doubled-stranded DNA viruses that cause respiratory infections. These viruses are particularly pathogenic in healthy and immune-compromised individuals, and currently, no adenovirus vaccine is available for the general public. The purpose of this review is to describe (i) the epidemiology and pathogenicity of human adenoviruses, (ii) the biological role of adenovirus vectors in gene therapy applications, and (iii) the potential role of exosomes in adenoviral infections.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "HIV pathogenicity; Gene therapy"

1

Kim, Vic Narry. "Analysis of components of HIV in the development of new gene transfer systems." Thesis, University of Oxford, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Singwi, Sanjeev. "HIV gene therapy using nucleases." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0001/MQ46100.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hemmerling, Deborah Ruth. "Retroviral vectors for anti-HIV gene therapy." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape8/PQDD_0004/NQ39538.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hotchkiss, Graham. "Towards ribozyme-mediated gene therapy of HIV-1 infections /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4007-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kotsopoulou, Ekaterini. "The unusual HIV-1 codon bias as a tool for anti-HIV strategies." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.312106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Maijgren, Steffensson Catharina. "Preclinical studies of ribozyme-mediated gene therapy for HIV-1 /." Stockholm : Karolinska institutet, 2004. http://diss.kib.ki.se/2004/91-7349-883-1/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

De, Silva Shamika Udayangi. "Chimeric adenoviruses as potential gene therapy vectors for HIV vaccination." Thesis, Royal Holloway, University of London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.435928.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, E. "Lentiviral gene therapy for HIV using TRIM-cyclophilin restriction factors." Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1362851/.

Full text
Abstract:
Lentiviral vector delivery of anti-HIV elements could provide the basis of alternative therapies against HIV, potentially providing long term protection after a single intervention. Some primate species have evolved restriction factors formed by the fusion of TRIM5α and Cyclophilin A (TRIM5Cyp) following retrotransposition of CypA cDNA into the TRIM5 gene, which provide potent resistance against certain lentiviruses. We have designed humanised versions of these proteins combining both TRIM5 and TRIM21 with CypA, and investigated their potential for use in gene therapy against HIV-1. Both TRIM5- and TRIM21-Cyp fusion proteins provided strong restriction of HIV-1 in all of the systems tested, including primary human T cells. However, TRIM5Cyp was shown to disrupt the antiretroviral effect of endogenous TRIM5α and rescue murine retrovirus infection, whereas TRIM21Cyp caused no interference. In contrast, neither TRIM5CypA nor TRIM21CypA expression affected the antiviral activity of endogenous TRIM21. In addition to TRIMCyp restriction factors, a second anti-HIV strategy was investigated using zinc finger nucleases (ZFNs) to knockout the HIV-1 co-receptor, CCR5. ZFNs introduce a double stranded break into the CCR5 gene, which can be restored by homology directed repair. Provision of a green fluorescent protein (GFP) or TRIM21Cyp donor template exploits this repair mechanism to allow site specific integration at the CCR5 locus, although at low efficiency. Using integrating vectors, we have shown that TRIMCyp mediated restriction is so potent that no additional inhibition was conferred by CCR5 knockout. In conclusion, delivery of TRIMCyp genes using lentiviral vectors could form the basis of an intracellular vaccination strategy against HIV-1, with TRIM21Cyp having benefits by maintaining endogenous TRIM function. With further optimisation to improve efficiency, this could be combined with ZFNs for site specific integration of the transgene and knockout of CCR5 to provide a dual method of HIV-1 inhibition.
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Xiaoxia. "Molecular studies on the action of APOBEC3G against HIV-1 and development of an APOBEC-based anti-HIV approach." American Society for Microbiology, 2011. http://hdl.handle.net/1993/23226.

Full text
Abstract:
Currently, the HIV pandemic remains a major global health challenge. In order to effectively control and cure HIV-1 infection, it is necessary to perform greater research on host-HIV interactions and develop novel preventive and therapeutic approaches. The human cytidine deaminase APOBEC3G (A3G) is the first identified host restriction factor, which can serve as an initial line of defense against HIV-1 by inducing lethal mutations on proviral DNA and disrupting viral reverse transcription and integration. In order to better understand the action of A3G on HIV-1 replication, my study was focused on characterizing the interplay between A3G and HIV-1 reverse transcriptase (RT). The results indicated that A3G directly bound to RT, which contributed to A3G-mediated inhibition of viral reverse transcription. Overexpression of the RT-binding polypeptide A3G65-132 was able to disrupt wild-type A3G and RT interaction, consequently attenuating the anti-HIV effect of A3G on HIV replication. While the potent antiviral activities of A3G make it an attractive candidate for gene therapy, the actions of A3G can be counteracted by HIV-1 Vif during wild-type HIV infection. In order to overcome Vif-mediated blockage and maximize the antiviral activity of A3G, this protein was fused with a virus-targeting polypeptide (R88) derived from HIV-1 Vpr, and various mutations were then introduced into R88-A3G fusion protein. Results showed that Vif binding mutants R88-A3GD128K and R88-A3GP129A exhibited very potent antiviral activity, and blocked HIV-1 replication in a CD4+ T lymphocyte cell line as well as human primary cells. In an attempt to further determine their potential against drug resistant viruses and viruses produced from latently infected cells, R88-A3GD128K was chosen and delivered by an inducible lentiviral vector system. Expression of R88-A3GD128K in actively and latently HIV-1 infected cells was shown to be able to inhibit the replication of both drug sensitive and resistant strains of HIV-1. In conclusion, this thesis has demonstrated one of the mechanisms that how A3G can disrupt HIV-1 reverse transcription. Meanwhile, an A3G-based anti-HIV-1 strategy has been developed, which provides a proof-of-principle for a new gene therapy approach against this deadly virus.
APA, Harvard, Vancouver, ISO, and other styles
10

Fuller, Maria. "A gene transfer system derived from human immunodeficiency virus type 1 (HIV-1)." Title page, table of contents, list of abbreviations and epitome only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phf9669.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "HIV pathogenicity; Gene therapy"

1

Bauer, Gerhard, and Joseph S. Anderson. Gene Therapy for HIV. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Singwi, Sanjeev. HIV gene therapy using nucleases. Ottawa: National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smith, Clay. Gene Therapy for HIV Infection. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-662-11821-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hengge, Ulrich R. Immunotreatment and gene therapy of HIV infection. Bremen: Uni-Med, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Berkhout, Ben, Hildegund C. J. Ertl, and Marc S. Weinberg, eds. Gene Therapy for HIV and Chronic Infections. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2432-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lombardi, Rocco Anthony. GAG and ENV trans-dominant mutants for use in ANTI-HIV-1 gene therapy. Ottawa: National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1937-, Matsushita Masaaki, and Fukunishi Isao, eds. Cutting edge medicine and liaison psychiatry: Psychiatric problems of organ transplantation, cancer, HIV/AIDS, and genetic therapy : proceedings of the 13th Tokyo Institute of Psychiatry International Symposium held in Tokyo on 29-30 September 1998. Amsterdam: Elsevier, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1957-, Smith Clay, ed. Gene therapy for HIV infection. Georgetown, Tex: R.G. Landes, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Berkhout, Ben, Hildegund C. J. Ertl, and Marc S. Weinberg. Gene Therapy for HIV and Chronic Infections. Springer, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bauer, Gerhard, and Joseph S. Anderson. Gene Therapy for HIV: From Inception to a Possible Cure. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "HIV pathogenicity; Gene therapy"

1

Morgan, Richard A. "Gene Therapy." In Immunology of HIV Infection, 577–94. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-0191-0_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bauer, Gerhard, and Joseph S. Anderson. "Gene Therapy Vectors." In Gene Therapy for HIV, 27–33. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bauer, Gerhard, and Joseph S. Anderson. "Principles of Gene Therapy." In Gene Therapy for HIV, 1–8. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bauer, Gerhard, and Joseph S. Anderson. "History of Gene Therapy." In Gene Therapy for HIV, 9–15. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bohnlein, Ernst. "HIV Gene Therapy: Current Status and Its Role in Therapy." In Gene Therapy, 91–101. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72160-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bauer, Gerhard, and Joseph S. Anderson. "Principles of HIV Gene Therapy." In Gene Therapy for HIV, 17–25. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bauer, Gerhard, and Joseph S. Anderson. "Stem Cells for HIV Gene Therapy." In Gene Therapy for HIV, 35–40. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bauer, Gerhard, and Joseph S. Anderson. "Animal Models Used in HIV Gene Therapy." In Gene Therapy for HIV, 41–47. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bauer, Gerhard, and Joseph S. Anderson. "Manufacturing of a GMP Grade Product for HIV Gene Therapy." In Gene Therapy for HIV, 49–54. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bauer, Gerhard, and Joseph S. Anderson. "Clinical Applications of HIV Gene Therapy." In Gene Therapy for HIV, 55–62. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HIV pathogenicity; Gene therapy"

1

Noy, Ariela. "Abstract PL04-02: HIV malignancies: From despair to gene therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-pl04-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Noy, Ariela. "Abstract PL04-02: HIV malignancies: From despair to gene therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-pl04-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'HIV pathogenicity; Gene therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography